Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly’s 2009 Growth Rides On Prasugrel; Advisory Committee’s Review Is Feb. 3

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm reports ’08 net loss from ImClone deal and Zyprexa settlement

You may also be interested in...



Mega-Merger Could Usher In New Era Of Consolidation

Given the looming patent cliff facing drug manufacturers and the lack of new products coming out of R&D to replace lost sales, it's hardly surprising that murmurings of industry consolidation are swirling

Mega-Merger Could Usher In New Era Of Consolidation

Given the looming patent cliff facing drug manufacturers and the lack of new products coming out of R&D to replace lost sales, it's hardly surprising that murmurings of industry consolidation are swirling

Lilly’s Zyprexa Off-Label Settlement: Record Fine, Routine Compliance Deal

Lilly agreed to pay $1.4 billion in criminal and civil fines and pled guilty to misbranding its antipsychotic drug Zyprexa in a settlement with the U.S. Department of Justice. Despite the record-breaking sum, however, the terms in the accompanying corporate integrity agreement are similar to previous CIAs

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068532

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel